5-APB, commonly marketed as 'benzofury' is a new psychoactive substance and erstwhile 'legal high' which has been implicated in 10 recent drug-related deaths in the UK. This drug was available on the internet and in 'head shops' and was one of the most commonly sold legal highs up until its recent UK temporary ban (UK Home Office). Despite its prominence, very little is known about its pharmacology. This study was undertaken to examine the pharmacology of 5-APB in vitro. We hypothesised that 5-APB would activate the dopamine and 5-HT systems which may underlie its putative stimulant and hallucinogenic effects. Autoradiographic studies showed that 5-APB displaced both [
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125 I] RTI-121 and [ 3 H] ketanserin from rat brain tissue suggesting affinity at the dopamine transporter and 5-HT 2 receptor sites respectively. Voltammetric studies in rat accumbens brain slices revealed that 5-APB slowed dopamine reuptake, and at high concentrations caused reverse transport of dopamine. 5-APB also caused vasoconstriction of rat aorta, an effect antagonised by the 5-HT 2A receptor antagonist ketanserin, and caused contraction of rat stomach fundus, which was reversed by the 5-HT 2B receptor antagonist RS-127445. These data show that 5-APB interacts with the dopamine transporter and is an agonist at the 5-HT 2A and 5-HT 2B receptors in the rat. Thus 5-APB's pharmacology is consistent with it having both stimulant and hallucinogenic properties. In addition, 5-APB's activity at the 5-HT 2B receptor may cause cardiotoxicity. © 2013 Elsevier Inc. All rights reserved.
Introduction
Until recently, two benzofuran compounds -5-and 6-APB (5-and 6-(2-aminopropyl)benzofuran) -were being sold as the "legal high"/"designer drug" 'Benzofury'. These drugs are structurally related to two other recreational drugs; Ecstasy (3,4, methylenedioxymethamphetamine, MDMA) and 3,4-methylenedioxyamphetamine (MDA). 5-and 6-APB are structural isomers and were first developed in the early 1990s (Monte et al., 1993) . There has been difficulty in separating the 5-and 6-APB isomers, and perhaps the occurrence of the 4-APB isomer, but chemical analysis can now differentiate these isomers (Stanczuk et al., 2013) . Anecdotal user reports suggest that benzofury has entactogenic and stimulant effects and that 5-APB is more potent than 6-APB. There is some suggestion that the drug may also have some psychedelic effects, but users do not appear to take 5-APB exclusively for this purpose. In the UK, Benzofury has been implicated in about 10 deaths since 2011. In all cases, 5-or 6-APB was found at postmortem, although because of polydrug use, it is often difficult to attribute death to a single drug (ICDP, personal communications). Anecdotal user reports suggest that this drug can cause hyperthermia, insomnia, increased heart rate and anxiety with some users reporting adverse effects similar to those produced by Ecstasy (ACMD report).
Psychostimulants are thought to mediate their rewarding effects through inhibition of the dopamine transporter or to cause direct dopamine release (Giros et al., 1996; Lee et al., 2001) . Hallucinogenic drugs such as LSD, on the other hand, would be expected to have efficacy at 5-HT 2A receptors (Passie et al., 2008 ). We thus first tested whether 5-APB could displace radioligands for the dopamine transporter and the 5-HT 2 receptors in rat brain tissue. Most drugs of abuse, but especially stimulants, increase dopamine efflux within the nucleus accumbens (Di Chiara and Imperato, 1988; Willuhn et al., 2010) . We next examined the effect of 5-APB in a functional study, using electrically evoked dopamine efflux in the rat accumbens brain slice, measured by fast cyclic voltammetry. Finally, given the potential cardiovascular effects of agonists at 5-HT 2 receptors (Dawson and Moffatt, 2012) we
